Congress orders Pentagon to study psilocybin for veteran PTSD

What it does

This bill requires the Department of Defense to review clinical trial data on psilocybin-containing mushrooms as a potential treatment for treatment-resistant PTSD in veterans and servicemembers, and report back to Congress within 180 days on safety, feasibility, and whether it could be used in military or VA settings. The bill does not authorize psilocybin use itself, but asks DoD to assess whether emerging research might inform future policy for troops and veterans who haven't responded to existing therapies.

Why we flagged it

The bill's core function is to direct DoD to conduct and report on a clinical assessment of emerging PTSD treatments. It is a procedural mandate for evidence review, not a substantive authorization or appropriation.

What the text implies

• The bill references a specific Arizona-sponsored trial (Passage and Fortitude trials) by name, which may signal legislative intent to fast-track review of that particular research pathway rather than a general emerging-treatment framework.
• Coordination with FDA and DEA on Schedule I substance research may create precedent for future psychedelic-assisted therapy pathways in federal healthcare, beyond PTSD.
• The 180-day timeline and FY2027 pilot-activity assessment suggest Congress expects DoD to move toward implementation, not merely study—this is a soft mandate for action, not just information-gathering.
• Continuity-of-care assessment between military and VA systems implies potential dual-track clinical infrastructure, which could require significant workforce and facility investment if pilots succeed.

Who it affects

Veterans and servicemembers with treatment-resistant PTSD—a population with elevated suicide risk and chronic impairment—gain access to rigorous review of a potentially life-saving emerging therapy. The bill mandates transparent assessment and coordination across federal agencies, with no apparent cost to the public and clear potential benefit to a vulnerable population.

Who stands to gain

• Clinical research organizations conducting psilocybin trials
• Pharmaceutical/biotech firms developing psychedelic-assisted therapies
• Military and VA healthcare infrastructure (if expanded access is implemented)

Named in the bill

Department of Defense, Assistant Secretary of Defense for Health Affairs, Defense Health Agency, Veterans Health Administration, Food and Drug Administration, Drug Enforcement Administration, State of Arizona, Passage Trial, Fortitude Trial, Federal Right to Try Act, Executive Order 14401

Where it stands

4 cosponsors: 3 Republicans, 1 Democrats.

• Jun 30, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 30, 2026 — Referred to House Committee on Armed Services · Congress.gov: “Referred to the House Committee on Armed Services”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.